Aqualab, the direct-to-retail vertical of Laborate Pharmaceuticals India Ltd., has surpassed the ₹100 crore revenue milestone within just three years of its inception and is now aiming to reach ₹250 crore by FY 2025–26.

The division, launched in 2022, has rapidly scaled its presence with a portfolio of more than 800 SKUs and a distribution base of over 500 retail stockists. Notably, Tier-II and Tier-III markets are emerging as key contributors, signalling the growing importance of non-metro demand in India’s pharma landscape.

Over the past two years, Aqualab has demonstrated consistent double-digit growth, recording revenues of ₹76 crore in FY 2022–23 and ₹108 crore in FY 2023–24. Its focus on affordability, accessibility, and last-mile delivery has enabled the division to penetrate smaller cities while maintaining its footprint across metropolitan markets.

“Crossing ₹100 crore in three years reflects the strong acceptance of our retail-first strategy. As we work towards achieving ₹250 crore by FY 25–26, expanding therapeutic categories and strengthening supply chain efficiency—particularly in non-metros, which will drive 42% of incremental growth—remain central to our strategy,” said Arpit Bhatia, Managing Director, Laborate Pharmaceuticals.

The growth trajectory of Aqualab aligns closely with India’s larger healthcare objectives, including the Make in India initiative and the government’s Production Linked Incentive (PLI) scheme, which is designed to boost domestic pharma manufacturing. According to industry estimates, India’s retail pharmacy segment stood at ₹18,700 crore in FY24 and is projected to reach ₹31,200 crore by FY32, growing at a CAGR of 6.6%—driven by stronger generic penetration, enhanced healthcare awareness, and organised distribution models.

To capture this opportunity, Aqualab is planning to expand into new therapeutic categories, strengthen its manufacturing capabilities, explore digital retail integration, and assess export markets. Laborate’s WHO-GMP and EU-GMP certified manufacturing infrastructure has been instrumental in enabling rapid scale-up while ensuring adherence to global quality standards—providing a strong platform for both domestic and international growth.

Also read: Terumo India Launches Terufusion™ Advanced Infusion Systems to Enhance Critical Care Precision and Safety

Established in 1985, Laborate Pharmaceuticals is among India’s prominent pharmaceutical companies with expertise in manufacturing, R&D, and international distribution. The company operates across multiple therapeutic categories, including cardiovascular, diabetes, CNS, pain management, and general medicines. With operations in 55 countries and advanced cGMP-compliant facilities, Laborate caters to both branded formulations and contract manufacturing.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!